144 related articles for article (PubMed ID: 32913236)
1. Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.
Grunt TW; Slany A; Semkova M; Colomer R; López-Rodríguez ML; Wuczkowski M; Wagner R; Gerner C; Stübiger G
Sci Rep; 2020 Sep; 10(1):14877. PubMed ID: 32913236
[TBL] [Abstract][Full Text] [Related]
2. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
3. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
Veigel D; Wagner R; Stübiger G; Wuczkowski M; Filipits M; Horvat R; Benhamú B; López-Rodríguez ML; Leisser A; Valent P; Grusch M; Hegardt FG; García J; Serra D; Auersperg N; Colomer R; Grunt TW
Int J Cancer; 2015 May; 136(9):2078-90. PubMed ID: 25302649
[TBL] [Abstract][Full Text] [Related]
5. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
Mullen GE; Yet L
Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
[TBL] [Abstract][Full Text] [Related]
6. The Pharmacological or Genetic Blockade of Endogenous
Grunt TW; Lemberger L; Colomer R; López Rodríguez ML; Wagner R
Front Oncol; 2021; 11():610885. PubMed ID: 33928023
[TBL] [Abstract][Full Text] [Related]
7. Galloyl esters of trans-stilbenes are inhibitors of FASN with anticancer activity on non-small cell lung cancer cells.
Tan YJ; Ali A; Tee SY; Teo JT; Xi Y; Go ML; Lam Y
Eur J Med Chem; 2019 Nov; 182():111597. PubMed ID: 31422225
[TBL] [Abstract][Full Text] [Related]
8. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.
Grube S; Dünisch P; Freitag D; Klausnitzer M; Sakr Y; Walter J; Kalff R; Ewald C
J Neurooncol; 2014 Jun; 118(2):277-287. PubMed ID: 24789255
[TBL] [Abstract][Full Text] [Related]
10. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
11. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells.
Deepa PR; Vandhana S; Krishnakumar S
Nutr Cancer; 2013; 65(2):311-6. PubMed ID: 23441619
[TBL] [Abstract][Full Text] [Related]
13. Targeting endogenous fatty acid synthesis stimulates the migration of ovarian cancer cells to adipocytes and promotes the transport of fatty acids from adipocytes to cancer cells.
Grunt TW; Wagner R; Ries A; Berghoff AS; Preusser M; Grusch M; Valent P
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214315
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
[TBL] [Abstract][Full Text] [Related]
15. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway.
Chuang HY; Lee YP; Lin WC; Lin YH; Hwang JJ
Sci Rep; 2019 Sep; 9(1):13284. PubMed ID: 31527721
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
Wang CJ; Li D; Danielson JA; Zhang EH; Dong Z; Miller KD; Li L; Zhang JT; Liu JY
Cancer Lett; 2021 Jul; 509():1-12. PubMed ID: 33813001
[TBL] [Abstract][Full Text] [Related]
17. Leucine deprivation inhibits proliferation and induces apoptosis of human breast cancer cells via fatty acid synthase.
Xiao F; Wang C; Yin H; Yu J; Chen S; Fang J; Guo F
Oncotarget; 2016 Sep; 7(39):63679-63689. PubMed ID: 27579768
[TBL] [Abstract][Full Text] [Related]
18. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
Sadowski MC; Pouwer RH; Gunter JH; Lubik AA; Quinn RJ; Nelson CC
Oncotarget; 2014 Oct; 5(19):9362-81. PubMed ID: 25313139
[TBL] [Abstract][Full Text] [Related]
19. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells.
Steller MD; Shaw TJ; Vanderhyden BC; Ethier JF
Mol Cancer Res; 2005 Jan; 3(1):50-61. PubMed ID: 15671249
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
